Free Imbruvica Program Cleared By HHS Inspector General
This article was originally published in The Pink Sheet Daily
Executive Summary
An advisory opinion says a program sponsored by Johnson & Johnson and AbbVie to provide up to 60 days of the cancer drug Imbruvica for free to patients who experience delays in receiving insurance coverage approval is at low risk of raising anti-kickback concerns.
You may also be interested in...
Acthar Proposed Giveaway Program Raises Kickback Concerns, OIG Says
High price of Mallinckrodt’s H.P. Acthar Gel is important factor in conclusion, HHS Office of Inspector General advisory opinion notes.
Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.